Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 28, 2024
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...
-
Mar 19, 2024
CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year...
-
Mar 7, 2024
March 7, 2024 During the latter part of 2023 and following notification by the World Health Organization that B/Yamagata lineage viruses have not been confirmed as detected in circulation since...
-
Feb 23, 2024
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe...
-
Feb 12, 2024
Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion1, up 17% NPAT $1.94 billion1 at CC3, up 20% NPATA $2.02 billion1,2 ,...
-
Feb 11, 2024
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
-
Feb 9, 2024
The FDA has been notified of the incident, which occurred at a plasma donation center
-
Feb 5, 2024
Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain...
-
Jan 16, 2024
Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024...
-
Jan 15, 2024
CSL's HEMGENIX® is a one-time, single-dose treatment for male adults with severe/moderately severe hemophilia B BERN, Switzerland, Jan. 15, 2024 /PRNewswire/ -- Global biotechnology leader CSL...